Fundamental Analysis of Catalyst Biosciences Inc - Growth / Value Index
CBIO - Valuation Highlights
Valuation Analysis
Tsr Value Index - Very Poor Score of 5.00
Price to Book Ratio of 47150.94 suggesting that it is very expensive
Book Value in last 3 years is trending down
Valuation Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Price to Earning | -31082.94 | -178.44 | -998.39 % | |
Price to Book | 47150.94 | 126.56 | 264.05 % | 251702 |
Price to Sales | -279746.42 | 1852.22 | 851.47 % | |
Enterprise Value to EBITDA Multiple | -141.79 | -208.58 | -1218.28 % |
CBIO - Profitability Highlights
Profitability Analysis
Gives Dividend Yield of 792.92 %
Strong Return On Capital Employed of 38.00
Company Earning excess return
During the past twelve months, the company has given a strong Net Margin of 900.00%
All key Trailing Twelve Months Margin growing by 15 %
Piotroski F Score - Very Poor Value of 2.0
Negative Net profit for last two years
In the last three years, the company has given poor Net Margin
In the last three years, the company has given poor Returns on Equity
In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Return On Equity | 0 | 0 | 0 % | -44.81 |
Return On Asset | -35.53 | -28.98 | 81.66 % | -15.82 |
Net Profit Margin | 900.00 | -1038.04 | 13.38 % | 0 |
Operating Profit Margin | 936.15 | -1084.51 | 9.46 % | 0 |
EBITDA Margin | 767.13 | -874.94 | 26.71 % | 0 |
Highlights
Market Cap | 885269 K |
Enterprise Value | 863641 K |
Price/Book TTM | 47150.94 |
Outstanding Share | 37978.10 K |
Float/ Outstanding Share | 4.82% |
Dividend Yield | 792.92 % |
Share Holding
Guru Numbers
Price/Graham No | 0 |
Peter Lynch Ratio | 0 |
Piotroski F Score | 2.00 |
Altman Z Score | 11.02 |
Sloan Ratio | 0.874 |
Peter Lynch Fair Value | 0 |
CBIO - Growth Highlights
Growth Analysis
Quarterly sales in last 5 years is trending up
Tsr Growth Index - Very Poor Score of 7.57
Companies' sales dropped by 89.18 % from last year
Company's Total Assets is Decreasing for last 3 years
Growth Key Fields
Field | TTM | YoY Growth | QoQ Growth |
---|---|---|---|
Revenue | -794000.00 | 89.18 % | % |
Gross Profit | -1592.00 K | 99.95 % | % |
EBITDA | -6091.00 K | 92.07 % | 36.15 % |
Net Profit | -7146.00 K | 90.63 % | 36.25 % |
EPS | -0.0007 | 90.90 % | NA |
CBIO - Stability Highlights
Stability Analysis
Altman Z Score of 11.02 suggests good Stability
Paid More Than 50% of Debt, Heading towards debt free
Debt to equity ratio has decreased and is lowest in last five years
Tsr Stability Index - Very Poor Score of 5.00
Company is unable to generate enough free cash to support the business.
Interest Coverage of -10.01
Stability Key Ratios
Ratio | Latest FY | Yoy Change | MRQ |
---|---|---|---|
Debt to Equity Ratio | -0.0018 | -103.64 % | 0 |
Cash Ratio | 1.29 | -61.06 % | |
Quick Ratio | 0 | 0 % | 2.22 |
Shareholders Equity | -76.25 | -203.30 % | |
Debt to EBITDA | -0.0055 | 75.76 % |
Historical Valuation Ratios of Catalyst Biosciences Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Catalyst Biosciences Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Catalyst Biosciences Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Catalyst Biosciences Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)